BioSpace News Archive

CollPlant Biotechnologies today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open.

The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. today announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia™ ATL5 , an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology, for Post-Traumatic Stress Disorder (PTSD).

DEM BioPharma, Inc. today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.

Proteovant Therapeutics today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and on PVTX-405, an IKZF2 molecular glue, at the Targeted Protein Degradation Europe Conference, March 28-30 in London.

VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update.

LumiraDx Limited announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st , 2023.

Simcere Pharmaceutical Group Limited (2096.HK) (Simcere) announced today that Simcere Zaiming, has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combination of SIM0235, a potential first-in-class humanized anti-tumor necrosis factor receptor 2 (TNFR2) monoclonal antibody, and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role.

Nanalysis Scientific Corp. announces that the Company’s Board of Directors has granted 335,000 stock options to Directors and Officers of the Company, pursuant to the Company’s stock option plan.

HeartBeam, Inc. (NASDAQ: BEAT) today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers.